Cervical Cancer Screening in HIV-Positive Women

Risk for cervical dysplasia in HPV-negative women is low, regardless of HIV status.

For HIV-seronegative women, recent cervical cancer screening guidelines have incorporated human papillomavirus (HPV) testing with screening intervals of 5 years in women with normal cytology who are also negative for oncogenic HPV infection (JW Womens Health Apr 12 2012). Should the same testing interval apply to women who are HIV positive? Investigators analyzed prospectively collected data on 420 HIV-positive and 279 HIV-negative women enrolled in the Women's Interagency HIV Study, who were followed for ≤9 years (median follow-up, 5 years) with semiannual Pap smears and HPV DNA testing. Endpoints were evidence of cervical precancer or cancer defined cytologically (high-grade squamous intraepithelial lesions or greater [HSIL+]) or histolog…

Reviewing Author

Anna Wald, MD, MPH

Disclosures

Consultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)

RoyaltiesUpToDate

Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris

Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases

Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)